ZnanyLekarz (Docplanner) stock
Private-market facts for current and former ZnanyLekarz (Docplanner) employees researching their stock.
Overview
Online healthcare booking platform operating across Europe and Latin America, enabling patients to find and schedule appointments with doctors and clinics.
Selling ZnanyLekarz (Docplanner) shares
Why shareholders consider selling
Shareholders in ZnanyLekarz (Docplanner) may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, ZnanyLekarz (Docplanner) does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell ZnanyLekarz (Docplanner) stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing ZnanyLekarz (Docplanner) shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of ZnanyLekarz (Docplanner) shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series F round and its reported $2.1B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for ZnanyLekarz (Docplanner) shareholders
Exploring equity in ZnanyLekarz (Docplanner) often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
ZnanyLekarz (Docplanner) most recently raised a Series F round in June 2024. The company was valued at $2.1B. Total funding raised to date is approximately $585M.
Lead investors in this round include Goldman Sachs and One Peak Partners.
Founders & company background
ZnanyLekarz (Docplanner) was founded in 2012 by Mariusz Gralewski and is headquartered in Warsaw, Poland.
Investors
Industry
Similar private companies
Frequently asked questions
- Is ZnanyLekarz (Docplanner) still a private company?
- Yes, ZnanyLekarz (Docplanner) is currently a private company.
- What is ZnanyLekarz (Docplanner)'s latest funding round?
- ZnanyLekarz (Docplanner)'s most recent known round is Series F, raised in June 2024.
- What is ZnanyLekarz (Docplanner)'s valuation?
- ZnanyLekarz (Docplanner)'s latest reported valuation is $2.1B.
- Who are the investors in ZnanyLekarz (Docplanner)?
- Notable investors include Goldman Sachs, One Peak Partners.
- Can I sell my ZnanyLekarz (Docplanner) stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands ZnanyLekarz (Docplanner) stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · ZnanyLekarz (Docplanner) data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.